首页 > 最新文献

Pathology & Oncology Research最新文献

英文 中文
Diagnostic and prognostic significance of keloid-like collagen remodeling patterns in the extracellular matrix of colorectal cancer. 大肠癌细胞外基质中瘢痕样胶原重塑模式的诊断和预后意义。
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-06-06 eCollection Date: 2024-01-01 DOI: 10.3389/pore.2024.1611789
Nauryzbay M Imanbayev, Yerbolat M Iztleuov, Yevgeniy K Kamyshanskiy, Aigul V Zhumasheva

Background: The desmoplastic reaction is considered a promising prognostic parameter for colorectal cancer. However, intermediate desmoplastic reaction is characterized by sizeable stromal heterogeneity, including both small amounts of keloid-like collagen (KC) in the fibrotic stroma and thick tufts of KC circumferentially surrounding cancer nests and occupying most of the fields of view. The present study aimed to evaluate the diagnostic and prognostic significance of KC histophenotyping with a quantitative visual assessment of its presence in the stroma of the invasive margin of TNM (The "tumor-node-metastasis" classification) stage II/III colorectal cancer (CRC).

Methods and results: 175 resected tumors from patients with TNM stage II/III CRC were examined. Keloid-like collagen was assessed according to Ueno H. criteria. KC was assessed at the primary tumor invasive margin using Hematoxylin & Eosin and Masson's trichrome staining. The cut-off point for KC was examined using "the best cutoff approach by log-rank test." Using a cutoff point of 30%, we histologically divided fibrous stroma in the invasive area into two groups: "type A"-KC ≤ 0.3 and "type B"-KC>0.3. Type A stroma was observed in 48% of patients, type B-in 52%. The association between collagen amount and 5-year recurrence-free survival (5-RFS) was assessed using Cox regression analysis. Kaplan-Meier analysis and log-rank tests were used to assess the significance of survival analysis. Analysis of categorical variables showed that increased KC in CRC stroma predicted adverse outcomes for 5-RFS (hazard ratio [HR] = 3.143, 95%, confidence interval [CI] = 1.643-6.012, p = 0.001). Moreover, in Kaplan-Meier analysis, the log-rank test showed that type B exhibited worse 5-RFS than type A (p = 0.000).

Conclusion: KC is an independent predictor of 5-year overall and RFS in patients with TNM stage II/III CRC treated with surgery, with worse survival rates when the amount of KC increases by >30%.

背景:脱鳞反应被认为是结直肠癌的一个有希望的预后参数。然而,中间脱鳞反应的特点是基质异质性较大,包括纤维化基质中的少量瘢痕样胶原(KC)和环绕癌巢并占据大部分视野的厚簇KC。本研究旨在评估 KC 组织分型在 TNM("肿瘤-结节-转移 "分类)II/III 期结直肠癌(CRC)浸润边缘基质中的定量视觉评估的诊断和预后意义:对175例TNM II/III期结直肠癌患者切除的肿瘤进行了检查。根据 Ueno H. 标准对瘢痕样胶原进行评估。使用苏木精和伊红以及马森三色染色法评估原发肿瘤浸润边缘的 KC。采用 "对数秩检验最佳截断点法 "对 KC 的截断点进行了研究。以 30% 为临界点,我们从组织学角度将浸润区的纤维基质分为两组:"A 型"--KC ≤ 0.3 和 "B 型"--KC>0.3。48%的患者出现了A型基质,52%的患者出现了B型基质。采用 Cox 回归分析评估了胶原蛋白量与 5 年无复发生存率(5-RFS)之间的关系。卡普兰-梅耶尔分析和对数秩检验用于评估生存分析的显著性。分类变量分析表明,CRC基质中KC的增加预示着5-RFS的不良结果(危险比[HR] = 3.143,95%,置信区间[CI] = 1.643-6.012,P = 0.001)。此外,在 Kaplan-Meier 分析中,对数秩检验显示 B 型患者的 5-RFS 比 A 型患者差(P = 0.000):结论:对于接受手术治疗的 TNM II/III 期 CRC 患者,KC 是 5 年总生存期和 RFS 的独立预测因子,当 KC 量增加 >30% 时,患者的生存率会更差。
{"title":"Diagnostic and prognostic significance of keloid-like collagen remodeling patterns in the extracellular matrix of colorectal cancer.","authors":"Nauryzbay M Imanbayev, Yerbolat M Iztleuov, Yevgeniy K Kamyshanskiy, Aigul V Zhumasheva","doi":"10.3389/pore.2024.1611789","DOIUrl":"10.3389/pore.2024.1611789","url":null,"abstract":"<p><strong>Background: </strong>The desmoplastic reaction is considered a promising prognostic parameter for colorectal cancer. However, intermediate desmoplastic reaction is characterized by sizeable stromal heterogeneity, including both small amounts of keloid-like collagen (KC) in the fibrotic stroma and thick tufts of KC circumferentially surrounding cancer nests and occupying most of the fields of view. The present study aimed to evaluate the diagnostic and prognostic significance of KC histophenotyping with a quantitative visual assessment of its presence in the stroma of the invasive margin of TNM (The \"tumor-node-metastasis\" classification) stage II/III colorectal cancer (CRC).</p><p><strong>Methods and results: </strong>175 resected tumors from patients with TNM stage II/III CRC were examined. Keloid-like collagen was assessed according to Ueno H. criteria. KC was assessed at the primary tumor invasive margin using Hematoxylin & Eosin and Masson's trichrome staining. The cut-off point for KC was examined using \"the best cutoff approach by log-rank test.\" Using a cutoff point of 30%, we histologically divided fibrous stroma in the invasive area into two groups: \"type A\"-KC ≤ 0.3 and \"type B\"-KC>0.3. Type A stroma was observed in 48% of patients, type B-in 52%. The association between collagen amount and 5-year recurrence-free survival (5-RFS) was assessed using Cox regression analysis. Kaplan-Meier analysis and log-rank tests were used to assess the significance of survival analysis. Analysis of categorical variables showed that increased KC in CRC stroma predicted adverse outcomes for 5-RFS (hazard ratio [HR] = 3.143, 95%, confidence interval [CI] = 1.643-6.012, <i>p</i> = 0.001). Moreover, in Kaplan-Meier analysis, the log-rank test showed that type B exhibited worse 5-RFS than type A (<i>p</i> = 0.000).</p><p><strong>Conclusion: </strong>KC is an independent predictor of 5-year overall and RFS in patients with TNM stage II/III CRC treated with surgery, with worse survival rates when the amount of KC increases by >30%.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611789"},"PeriodicalIF":2.3,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11186984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141432551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastric epithelial neoplasm of fundic-gland mucosa lineage: representative of the low atypia differentiated gastric tumor and Ki67 may help in their identification. 胃底-胃黏膜系的胃上皮肿瘤:低不典型性分化型胃肿瘤的代表,Ki67 可能有助于鉴别。
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-05-30 eCollection Date: 2024-01-01 DOI: 10.3389/pore.2024.1611734
Houqiang Li, Lanqing Zheng, Guodong Zhong, Xunbin Yu, Xia Zhang, Linying Chen, Xin Chen

Background: Gastric epithelial neoplasm of the fundic-gland mucosa lineages (GEN-FGMLs) are rare forms of gastric tumors that encompass oxyntic gland adenoma (OGA), gastric adenocarcinoma of the fundic-gland type (GA-FG), and gastric adenocarcinoma of the fundic-gland mucosa type (GA-FGM). There is no consensus on the cause, classification, and clinicopathological features of GEN-FGMLs, and misdiagnosis is common because of similarities in symptoms.

Methods: 37 cases diagnosed with GEN-FGMLs were included in this study. H&E-stained slides were reviewed and clinicopathological parameters were recorded. Immunohistochemical staining was conducted for MUC2, MUC5AC, MUC6, CD10, CD56, synaptophysin, chromograninA, p53, Ki67, pepsinogen-I, H+/K+-ATPase and Desmin.

Results: The patients' ages ranged from 42 to 79 years, with a median age of 60. 17 were male and 20 were female. Morphologically, 19 OGAs, 16 GA-FGs, and two GA-FGMs were identified. Histopathological similarities exist between OGA, GA-FG, and GA-FGM. The tumors demonstrated well-formed glands, expanding with dense growth patterns comprising pale, blue-grey columnar cells with mild nuclear atypia. These cells resembled fundic gland cells. None of the OGA invaded the submucosal layer. The normal gastric pit epithelium covered the entire surface of the OGA and GA-FG, but the dysplasia pit epithelium covered the GA-FGM. Non-atrophic gastritis was observed in more than half of the background mucosa. All cases were diffusely positive for MUC6 and pepsinogen-I on immunohistochemistry. H+/K+-ATPase staining was negative or showed a scattered pattern in most cases. MUC5AC was expressed on the surface of GA-FGMs. p53 was focally expressed and the Ki67 index was low (1%-20%). Compared with OGA, GA-FG and GA-FGM were more prominent in the macroscopic view (p < 0.05) and had larger sizes (p < 0.0001). Additionally, GA-FG and GA-FGM exhibited higher Ki67 indices than OGA (p < 0.0001). Specimens with Ki-67 proliferation indices >2.5% and size >4.5 mm are more likely to be diagnosed with GA-FG and GA-FGM than OGA.

Conclusion: GEN-FGMLs are group of well-differentiated gastric tumors with favourable biological behaviours, low cellular atypia, and low proliferation. Immunohistochemistry is critical for confirming diagnosis. Compared with OGA, GA-FG and GA-FGM have larger sizes and higher Ki67 proliferation indices, indicating that they play a critical role in the identification of GEN-FGML. Pathologists and endoscopists should be cautious to prevent misdiagnosis and overtreatment, especially in biopsy specimens.

背景:胃底腺黏膜上皮肿瘤(GEN-FGMLs)是一种罕见的胃肿瘤,包括胃底腺腺瘤(OGA)、胃底腺型胃腺癌(GA-FG)和胃底腺黏膜型胃腺癌(GA-FGM)。关于 GEN-FGMLs 的病因、分类和临床病理特征尚未达成共识,而且由于症状相似,误诊也很常见。方法:本研究共纳入 37 例确诊为 GEN-FGMLs 的病例,对 H&E 染色切片进行复查,并记录临床病理参数。对 MUC2、MUC5AC、MUC6、CD10、CD56、突触素、chromograninA、p53、Ki67、胃蛋白酶原-I、H+/K+-ATPase 和 Desmin 进行免疫组化染色:患者年龄从 42 岁到 79 岁不等,中位年龄为 60 岁。男性 17 人,女性 20 人。从形态上看,共发现 19 例 OGA、16 例 GA-FG 和 2 例 GA-FGM。OGA、GA-FG 和 GA-FGM 在组织病理学上有相似之处。这些肿瘤表现为形态良好的腺体,以密集的生长模式扩张,由浅蓝灰色柱状细胞组成,核轻度不典型。这些细胞类似眼底腺细胞。没有一个 OGA 肿瘤侵入粘膜下层。正常的胃凹陷上皮覆盖了OGA和GA-FG的整个表面,但发育不良的凹陷上皮覆盖了GA-FGM。半数以上的背景粘膜出现非萎缩性胃炎。免疫组化结果显示,所有病例的MUC6和胃蛋白酶原-I均呈弥漫阳性。大多数病例的H+/K+-ATP酶染色为阴性或呈散在模式。GA-FGM 表面表达 MUC5AC,p53 呈局灶性表达,Ki67 指数较低(1%-20%)。与OGA相比,GA-FG和GA-FGM在宏观上更突出(p < 0.05),体积更大(p < 0.0001)。此外,GA-FG 和 GA-FGM 的 Ki67 指数高于 OGA(P < 0.0001)。与OGA相比,Ki-67增殖指数大于2.5%、大小大于4.5毫米的标本更有可能被诊断为GA-FG和GA-FGM:结论:GEN-FGMLs是一组分化良好的胃肿瘤,具有良好的生物学行为、低细胞不典型性和低增殖性。免疫组化是确诊的关键。与OGA相比,GA-FG和GA-FGM的体积更大,Ki67增殖指数更高,这表明它们在GEN-FGML的鉴别中起着关键作用。病理学家和内镜医师应谨慎从事,防止误诊和过度治疗,尤其是活检标本。
{"title":"Gastric epithelial neoplasm of fundic-gland mucosa lineage: representative of the low atypia differentiated gastric tumor and Ki67 may help in their identification.","authors":"Houqiang Li, Lanqing Zheng, Guodong Zhong, Xunbin Yu, Xia Zhang, Linying Chen, Xin Chen","doi":"10.3389/pore.2024.1611734","DOIUrl":"10.3389/pore.2024.1611734","url":null,"abstract":"<p><strong>Background: </strong>Gastric epithelial neoplasm of the fundic-gland mucosa lineages (GEN-FGMLs) are rare forms of gastric tumors that encompass oxyntic gland adenoma (OGA), gastric adenocarcinoma of the fundic-gland type (GA-FG), and gastric adenocarcinoma of the fundic-gland mucosa type (GA-FGM). There is no consensus on the cause, classification, and clinicopathological features of GEN-FGMLs, and misdiagnosis is common because of similarities in symptoms.</p><p><strong>Methods: </strong>37 cases diagnosed with GEN-FGMLs were included in this study. H&E-stained slides were reviewed and clinicopathological parameters were recorded. Immunohistochemical staining was conducted for MUC2, MUC5AC, MUC6, CD10, CD56, synaptophysin, chromograninA, p53, Ki67, pepsinogen-I, H<sup>+</sup>/K<sup>+</sup>-ATPase and Desmin.</p><p><strong>Results: </strong>The patients' ages ranged from 42 to 79 years, with a median age of 60. 17 were male and 20 were female. Morphologically, 19 OGAs, 16 GA-FGs, and two GA-FGMs were identified. Histopathological similarities exist between OGA, GA-FG, and GA-FGM. The tumors demonstrated well-formed glands, expanding with dense growth patterns comprising pale, blue-grey columnar cells with mild nuclear atypia. These cells resembled fundic gland cells. None of the OGA invaded the submucosal layer. The normal gastric pit epithelium covered the entire surface of the OGA and GA-FG, but the dysplasia pit epithelium covered the GA-FGM. Non-atrophic gastritis was observed in more than half of the background mucosa. All cases were diffusely positive for MUC6 and pepsinogen-I on immunohistochemistry. H<sup>+</sup>/K<sup>+</sup>-ATPase staining was negative or showed a scattered pattern in most cases. MUC5AC was expressed on the surface of GA-FGMs. p53 was focally expressed and the Ki67 index was low (1%-20%). Compared with OGA, GA-FG and GA-FGM were more prominent in the macroscopic view (<i>p</i> < 0.05) and had larger sizes (<i>p</i> < 0.0001). Additionally, GA-FG and GA-FGM exhibited higher Ki67 indices than OGA (<i>p</i> < 0.0001). Specimens with Ki-67 proliferation indices >2.5% and size >4.5 mm are more likely to be diagnosed with GA-FG and GA-FGM than OGA.</p><p><strong>Conclusion: </strong>GEN-FGMLs are group of well-differentiated gastric tumors with favourable biological behaviours, low cellular atypia, and low proliferation. Immunohistochemistry is critical for confirming diagnosis. Compared with OGA, GA-FG and GA-FGM have larger sizes and higher Ki67 proliferation indices, indicating that they play a critical role in the identification of GEN-FGML. Pathologists and endoscopists should be cautious to prevent misdiagnosis and overtreatment, especially in biopsy specimens.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611734"},"PeriodicalIF":2.3,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11169639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction: Case report: A rare case of tumor-to-tumor metastasis: metastatic lobular breast carcinoma to clear cell renal cell carcinoma. 撤回:病例报告:一例罕见的肿瘤间转移:透明细胞肾细胞癌转移至乳腺小叶癌。
IF 2.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-04-05 eCollection Date: 2024-01-01 DOI: 10.3389/pore.2024.1611784

[This retracts the article DOI: 10.3389/pore.2023.1611204.].

[本文撤消了文章 DOI:10.3389/pore.2023.1611204.]。
{"title":"Retraction: Case report: A rare case of tumor-to-tumor metastasis: metastatic lobular breast carcinoma to clear cell renal cell carcinoma.","authors":"","doi":"10.3389/pore.2024.1611784","DOIUrl":"https://doi.org/10.3389/pore.2024.1611784","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.3389/pore.2023.1611204.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611784"},"PeriodicalIF":2.8,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11027495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140852336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction: MiR-184 retarded the proliferation, invasiveness and migration of glioblastoma cells by repressing stanniocalcin-2. 撤回:MiR-184 通过抑制 stanniocalcin-2 延缓胶质母细胞瘤细胞的增殖、侵袭性和迁移
IF 2.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-03-28 eCollection Date: 2024-01-01 DOI: 10.3389/pore.2024.1611767

[This retracts the article DOI: 10.1007/s12253-017-0298-z.].

[本文撤回文章 DOI:10.1007/s12253-017-0298-z]。
{"title":"Retraction: MiR-184 retarded the proliferation, invasiveness and migration of glioblastoma cells by repressing stanniocalcin-2.","authors":"","doi":"10.3389/pore.2024.1611767","DOIUrl":"https://doi.org/10.3389/pore.2024.1611767","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1007/s12253-017-0298-z.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611767"},"PeriodicalIF":2.8,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11007041/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140858458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary. 更正:接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的并发症和预后:来自匈牙利的一项真实世界、全国范围的回顾性研究。
IF 2.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-03-21 eCollection Date: 2024-01-01 DOI: 10.3389/pore.2024.1611758
Peter Batar, Hussain Alizadeh, Gyorgy Rokszin, Zsolt Abonyi-Toth, Judit Demeter

[This corrects the article DOI: 10.3389/pore.2024.1611497.].

[此处更正了文章 DOI:10.3389/pore.2024.1611497]。
{"title":"Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary.","authors":"Peter Batar, Hussain Alizadeh, Gyorgy Rokszin, Zsolt Abonyi-Toth, Judit Demeter","doi":"10.3389/pore.2024.1611758","DOIUrl":"https://doi.org/10.3389/pore.2024.1611758","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/pore.2024.1611497.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611758"},"PeriodicalIF":2.8,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10991778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Positive correlation between persistence of medical nutrition therapy and overall survival in patients with head and neck cancer. 头颈部癌症患者持续接受医学营养治疗与总生存期之间存在正相关。
IF 2.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-03-15 eCollection Date: 2024-01-01 DOI: 10.3389/pore.2024.1611664
Andrea Molnár, Erzsébet Pálfi, Barbara Belák, Célia Blasszauer, Dániel Reibl, József Lövey

Background: Several factors can affect overall survival of head and neck cancer (HNC) patients, including characteristics of the cancer disease and response to treatments. However, patients' nutritional status and the effectiveness of medical nutrition therapy (MNT) can also impact overall survival. The primary goal of our research was to collect real-life data on the use of MNT in HNC patients and to specifically investigate the correlation between survival and the duration of uninterrupted (persistent) nutrition. Method: The data of this retrospective, analytical, cohort study was collected from electronic healthcare records from the Hungarian National Health Insurance Fund Management. Overall, 38,675 HNC patients' data of the period between 2012 and 2021 was used. We applied multi-step exclusions to identify patient groups accurately and to avoid biasing factors. Statistical analysis was done by the Kaplan-Meier method, log-rank test, and Cox regression analysis. Results: Throughout the investigated period 16,871 (64%) patients received MNT therapy out of 26,253 newly diagnosed patients (≥18 years). In terms of the persistence of MNT, we divided the patients into three groups (1-3; 4-6; ≥7-month duration of MNT). When comparing these groups, we found that patients receiving long-term (≥7 months) MNT had a significantly longer overall survival (p < 0.0001) than those who received MNT for a shorter duration, both in locally advanced and recurrent/metastatic cases. Conclusion: The main outcome of the study is that there is a positive correlation between the persistence of MNT and the overall survival in HNC patients when nutritional intervention lasts several months. It highlights the responsibility of the specialists during the patient journey to use MNT early and to continue its use for as long as it is beneficial to the patients.

背景:影响头颈癌(HNC)患者总生存期的因素有很多,包括癌症疾病的特征和对治疗的反应。然而,患者的营养状况和医学营养疗法(MNT)的效果也会影响总生存率。我们研究的主要目的是收集有关 HNC 患者使用 MNT 的真实数据,并特别调查生存期与不间断(持续)营养时间之间的相关性。研究方法这项回顾性、分析性、队列研究的数据来自匈牙利国家医疗保险基金管理部门的电子医疗记录。总共使用了 38675 名 HNC 患者在 2012 年至 2021 年期间的数据。我们采用了多步骤排除法,以准确识别患者群体并避免偏倚因素。统计分析采用卡普兰-梅耶法、对数秩检验和考克斯回归分析。研究结果在整个调查期间,26253 名新确诊患者(≥18 岁)中有 16871 名(64%)接受了 MNT 治疗。根据 MNT 的持续时间,我们将患者分为三组(1-3 个月;4-6 个月;MNT 持续时间≥7 个月)。在比较这些组别时,我们发现,无论是局部晚期病例还是复发/转移病例,接受长期(≥7 个月)MNT 的患者的总生存期(P < 0.0001)明显长于接受 MNT 时间较短的患者。结论本研究的主要结果是,在营养干预持续数月的情况下,HNC 患者的 MNT 持续时间与总生存期呈正相关。研究强调了专科医生在患者治疗过程中的责任,即尽早使用 MNT,并在对患者有益的情况下持续使用。
{"title":"Positive correlation between persistence of medical nutrition therapy and overall survival in patients with head and neck cancer.","authors":"Andrea Molnár, Erzsébet Pálfi, Barbara Belák, Célia Blasszauer, Dániel Reibl, József Lövey","doi":"10.3389/pore.2024.1611664","DOIUrl":"10.3389/pore.2024.1611664","url":null,"abstract":"<p><p><b>Background:</b> Several factors can affect overall survival of head and neck cancer (HNC) patients, including characteristics of the cancer disease and response to treatments. However, patients' nutritional status and the effectiveness of medical nutrition therapy (MNT) can also impact overall survival. The primary goal of our research was to collect real-life data on the use of MNT in HNC patients and to specifically investigate the correlation between survival and the duration of uninterrupted (persistent) nutrition. <b>Method:</b> The data of this retrospective, analytical, cohort study was collected from electronic healthcare records from the Hungarian National Health Insurance Fund Management. Overall, 38,675 HNC patients' data of the period between 2012 and 2021 was used. We applied multi-step exclusions to identify patient groups accurately and to avoid biasing factors. Statistical analysis was done by the Kaplan-Meier method, log-rank test, and Cox regression analysis. <b>Results:</b> Throughout the investigated period 16,871 (64%) patients received MNT therapy out of 26,253 newly diagnosed patients (≥18 years). In terms of the persistence of MNT, we divided the patients into three groups (1-3; 4-6; ≥7-month duration of MNT). When comparing these groups, we found that patients receiving long-term (≥7 months) MNT had a significantly longer overall survival (<i>p</i> < 0.0001) than those who received MNT for a shorter duration, both in locally advanced and recurrent/metastatic cases. <b>Conclusion:</b> The main outcome of the study is that there is a positive correlation between the persistence of MNT and the overall survival in HNC patients when nutritional intervention lasts several months. It highlights the responsibility of the specialists during the patient journey to use MNT early and to continue its use for as long as it is beneficial to the patients.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611664"},"PeriodicalIF":2.8,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10979420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140336507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
mTOR hyperactivity and RICTOR amplification as targets for personalized treatments in malignancies. 作为恶性肿瘤个性化治疗靶点的 mTOR 过度活跃和 RICTOR 扩增。
IF 2.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-03-07 eCollection Date: 2024-01-01 DOI: 10.3389/pore.2024.1611643
Dániel Sztankovics, Dorottya Moldvai, Gábor Petővári, Titanilla Dankó, Fatime Szalai, Risa Miyaura, Viktória Varga, Noémi Nagy, Gergő Papp, Judit Pápay, Ildikó Krencz, Anna Sebestyén

The increasing knowledge of molecular alterations in malignancies, including mutations and regulatory failures in the mTOR (mechanistic target of rapamycin) signaling pathway, highlights the importance of mTOR hyperactivity as a validated target in common and rare malignancies. This review summarises recent findings on the characterization and prognostic role of mTOR kinase complexes (mTORC1 and mTORC2) activity regarding differences in their function, structure, regulatory mechanisms, and inhibitor sensitivity. We have recently identified new tumor types with RICTOR (rapamycin-insensitive companion of mTOR) amplification and associated mTORC2 hyperactivity as useful potential targets for developing targeted therapies in lung cancer and other newly described malignancies. The activity of mTOR complexes is recommended to be assessed and considered in cancers before mTOR inhibitor therapy, as current first-generation mTOR inhibitors (rapamycin and analogs) can be ineffective in the presence of mTORC2 hyperactivity. We have introduced and proposed a marker panel to determine tissue characteristics of mTOR activity in biopsy specimens, patient materials, and cell lines. Ongoing phase trials of new inhibitors and combination therapies are promising in advanced-stage patients selected by genetic alterations, molecular markers, and/or protein expression changes in the mTOR signaling pathway. Hopefully, the summarized results, our findings, and the suggested characterization of mTOR activity will support therapeutic decisions.

随着人们对恶性肿瘤分子改变(包括雷帕霉素机理靶点)信号通路中的突变和调控失灵的认识不断加深,mTOR活性亢进作为常见和罕见恶性肿瘤中的一个有效靶点的重要性凸显出来。这篇综述总结了有关 mTOR 激酶复合物(mTORC1 和 mTORC2)活性的特征和预后作用的最新研究成果,涉及它们在功能、结构、调节机制和抑制剂敏感性方面的差异。我们最近发现了一些新的肿瘤类型,它们具有 RICTOR(雷帕霉素不敏感的 mTOR 伴体)扩增和相关的 mTORC2 活性亢进,是开发肺癌和其他新描述的恶性肿瘤靶向疗法的有用潜在靶点。由于目前的第一代 mTOR 抑制剂(雷帕霉素及其类似物)在 mTORC2 活性亢进的情况下可能无效,因此建议在使用 mTOR 抑制剂治疗癌症之前评估并考虑 mTOR 复合物的活性。我们已经引入并提出了一个标记面板,用于确定活检标本、患者材料和细胞系中 mTOR 活性的组织特征。对于通过基因改变、分子标记和/或 mTOR 信号通路蛋白表达变化筛选出的晚期患者,正在进行的新型抑制剂和联合疗法的阶段性试验前景广阔。希望上述总结的结果、我们的发现以及对 mTOR 活性特征的建议能为治疗决策提供支持。
{"title":"mTOR hyperactivity and <i>RICTOR</i> amplification as targets for personalized treatments in malignancies.","authors":"Dániel Sztankovics, Dorottya Moldvai, Gábor Petővári, Titanilla Dankó, Fatime Szalai, Risa Miyaura, Viktória Varga, Noémi Nagy, Gergő Papp, Judit Pápay, Ildikó Krencz, Anna Sebestyén","doi":"10.3389/pore.2024.1611643","DOIUrl":"10.3389/pore.2024.1611643","url":null,"abstract":"<p><p>The increasing knowledge of molecular alterations in malignancies, including mutations and regulatory failures in the mTOR (mechanistic target of rapamycin) signaling pathway, highlights the importance of mTOR hyperactivity as a validated target in common and rare malignancies. This review summarises recent findings on the characterization and prognostic role of mTOR kinase complexes (mTORC1 and mTORC2) activity regarding differences in their function, structure, regulatory mechanisms, and inhibitor sensitivity. We have recently identified new tumor types with <i>RICTOR</i> (rapamycin-insensitive companion of mTOR) amplification and associated mTORC2 hyperactivity as useful potential targets for developing targeted therapies in lung cancer and other newly described malignancies. The activity of mTOR complexes is recommended to be assessed and considered in cancers before mTOR inhibitor therapy, as current first-generation mTOR inhibitors (rapamycin and analogs) can be ineffective in the presence of mTORC2 hyperactivity. We have introduced and proposed a marker panel to determine tissue characteristics of mTOR activity in biopsy specimens, patient materials, and cell lines. Ongoing phase trials of new inhibitors and combination therapies are promising in advanced-stage patients selected by genetic alterations, molecular markers, and/or protein expression changes in the mTOR signaling pathway. Hopefully, the summarized results, our findings, and the suggested characterization of mTOR activity will support therapeutic decisions.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611643"},"PeriodicalIF":2.8,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140185094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction: High expression of long noncoding RNA HOTAIRM1 is associated with the proliferation and migration in pancreatic ductal adenocarcinoma. 撤回:长非编码 RNA HOTAIRM1 的高表达与胰腺导管腺癌的增殖和迁移有关
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-03-04 eCollection Date: 2024-01-01 DOI: 10.3389/pore.2024.1611728

[This retracts the article DOI: 10.1007/s12253-018-00570-4.].

[本文撤回了文章 DOI:10.1007/s12253-018-00570-4]。
{"title":"Retraction: High expression of long noncoding RNA HOTAIRM1 is associated with the proliferation and migration in pancreatic ductal adenocarcinoma.","authors":"","doi":"10.3389/pore.2024.1611728","DOIUrl":"https://doi.org/10.3389/pore.2024.1611728","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1007/s12253-018-00570-4.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611728"},"PeriodicalIF":2.3,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stereotactic body radiotherapy in lung cancer: a contemporary review. 肺癌的立体定向体放射治疗:当代综述。
IF 2.8 4区 医学 Q3 ONCOLOGY Pub Date : 2024-02-27 eCollection Date: 2024-01-01 DOI: 10.3389/pore.2024.1611709
Emese Csiki, Mihály Simon, Judit Papp, Márton Barabás, Johanna Mikáczó, Kristóf Gál, David Sipos, Árpád Kovács

The treatment of early stage non-small cell lung cancer (NSCLC) has improved enormously in the last two decades. Although surgery is not the only choice, lobectomy is still the gold standard treatment type for operable patients. For inoperable patients stereotactic body radiotherapy (SBRT) should be offered, reaching very high local control and overall survival rates. With SBRT we can precisely irradiate small, well-defined lesions with high doses. To select the appropriate fractionation schedule it is important to determine the size, localization and extent of the lung tumor. The introduction of novel and further developed planning (contouring guidelines, diagnostic image application, planning systems) and delivery techniques (motion management, image guided radiotherapy) led to lower rates of side effects and more conformal target volume coverage. The purpose of this study is to summarize the current developments, randomised studies, guidelines about lung SBRT, with emphasis on the possibility of increasing local control and overall rates in "fit," operable patients as well, so SBRT would be eligible in place of surgery.

在过去二十年里,早期非小细胞肺癌(NSCLC)的治疗有了极大的改善。虽然手术不是唯一的选择,但肺叶切除术仍是可手术患者的金标准治疗方式。对于无法手术的患者,应采用立体定向体放射治疗(SBRT),其局部控制率和总生存率都非常高。通过 SBRT,我们可以用大剂量精确照射小而清晰的病灶。要选择合适的分次计划,必须确定肺部肿瘤的大小、定位和范围。新型和进一步发展的计划(轮廓指引、诊断图像应用、计划系统)和给药技术(运动管理、图像引导放疗)的引入降低了副作用的发生率,并使靶体积覆盖更加适形。本研究的目的是总结有关肺部SBRT的最新进展、随机研究和指南,重点是能否提高 "适合 "手术患者的局部控制率和总有效率,从而使SBRT有资格取代手术。
{"title":"Stereotactic body radiotherapy in lung cancer: a contemporary review.","authors":"Emese Csiki, Mihály Simon, Judit Papp, Márton Barabás, Johanna Mikáczó, Kristóf Gál, David Sipos, Árpád Kovács","doi":"10.3389/pore.2024.1611709","DOIUrl":"10.3389/pore.2024.1611709","url":null,"abstract":"<p><p>The treatment of early stage non-small cell lung cancer (NSCLC) has improved enormously in the last two decades. Although surgery is not the only choice, lobectomy is still the gold standard treatment type for operable patients. For inoperable patients stereotactic body radiotherapy (SBRT) should be offered, reaching very high local control and overall survival rates. With SBRT we can precisely irradiate small, well-defined lesions with high doses. To select the appropriate fractionation schedule it is important to determine the size, localization and extent of the lung tumor. The introduction of novel and further developed planning (contouring guidelines, diagnostic image application, planning systems) and delivery techniques (motion management, image guided radiotherapy) led to lower rates of side effects and more conformal target volume coverage. The purpose of this study is to summarize the current developments, randomised studies, guidelines about lung SBRT, with emphasis on the possibility of increasing local control and overall rates in \"fit,\" operable patients as well, so SBRT would be eligible in place of surgery.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611709"},"PeriodicalIF":2.8,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10928908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140111098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Geroscience and pathology: a new frontier in understanding age-related diseases. 老年科学与病理学:了解老年相关疾病的新领域。
IF 2.3 4区 医学 Q3 ONCOLOGY Pub Date : 2024-02-23 eCollection Date: 2024-01-01 DOI: 10.3389/pore.2024.1611623
Monika Fekete, David Major, Agnes Feher, Vince Fazekas-Pongor, Andrea Lehoczki

Geroscience, a burgeoning discipline at the intersection of aging and disease, aims to unravel the intricate relationship between the aging process and pathogenesis of age-related diseases. This paper explores the pivotal role played by geroscience in reshaping our understanding of pathology, with a particular focus on age-related diseases. These diseases, spanning cardiovascular and cerebrovascular disorders, malignancies, and neurodegenerative conditions, significantly contribute to the morbidity and mortality of older individuals. We delve into the fundamental cellular and molecular mechanisms underpinning aging, including mitochondrial dysfunction and cellular senescence, and elucidate their profound implications for the pathogenesis of various age-related diseases. Emphasis is placed on the importance of assessing key biomarkers of aging and biological age within the realm of pathology. We also scrutinize the interplay between cellular senescence and cancer biology as a central area of focus, underscoring its paramount significance in contemporary pathological research. Moreover, we shed light on the integration of anti-aging interventions that target fundamental aging processes, such as senolytics, mitochondria-targeted treatments, and interventions that influence epigenetic regulation within the domain of pathology research. In conclusion, the integration of geroscience concepts into pathological research heralds a transformative paradigm shift in our understanding of disease pathogenesis and promises breakthroughs in disease prevention and treatment.

老年科学是衰老与疾病交叉领域的一门新兴学科,旨在揭示衰老过程与老年相关疾病发病机制之间错综复杂的关系。本文探讨了老年科学在重塑我们对病理学的认识方面所发挥的关键作用,尤其侧重于老年相关疾病。这些疾病包括心脑血管疾病、恶性肿瘤和神经退行性疾病,严重影响了老年人的发病率和死亡率。我们深入研究衰老的基本细胞和分子机制,包括线粒体功能障碍和细胞衰老,并阐明它们对各种老年相关疾病发病机制的深远影响。重点是在病理学领域评估衰老和生物年龄的关键生物标志物的重要性。我们还将细胞衰老与癌症生物学之间的相互作用作为一个中心领域进行仔细研究,强调其在当代病理学研究中的重要意义。此外,我们还阐明了针对基本衰老过程的抗衰老干预措施(如衰老素、线粒体靶向治疗)与影响病理学研究领域表观遗传调控的干预措施之间的整合。总之,将全球科学概念融入病理学研究,预示着我们对疾病发病机制的理解将发生变革性的范式转变,并有望在疾病预防和治疗方面取得突破。
{"title":"Geroscience and pathology: a new frontier in understanding age-related diseases.","authors":"Monika Fekete, David Major, Agnes Feher, Vince Fazekas-Pongor, Andrea Lehoczki","doi":"10.3389/pore.2024.1611623","DOIUrl":"10.3389/pore.2024.1611623","url":null,"abstract":"<p><p>Geroscience, a burgeoning discipline at the intersection of aging and disease, aims to unravel the intricate relationship between the aging process and pathogenesis of age-related diseases. This paper explores the pivotal role played by geroscience in reshaping our understanding of pathology, with a particular focus on age-related diseases. These diseases, spanning cardiovascular and cerebrovascular disorders, malignancies, and neurodegenerative conditions, significantly contribute to the morbidity and mortality of older individuals. We delve into the fundamental cellular and molecular mechanisms underpinning aging, including mitochondrial dysfunction and cellular senescence, and elucidate their profound implications for the pathogenesis of various age-related diseases. Emphasis is placed on the importance of assessing key biomarkers of aging and biological age within the realm of pathology. We also scrutinize the interplay between cellular senescence and cancer biology as a central area of focus, underscoring its paramount significance in contemporary pathological research. Moreover, we shed light on the integration of anti-aging interventions that target fundamental aging processes, such as senolytics, mitochondria-targeted treatments, and interventions that influence epigenetic regulation within the domain of pathology research. In conclusion, the integration of geroscience concepts into pathological research heralds a transformative paradigm shift in our understanding of disease pathogenesis and promises breakthroughs in disease prevention and treatment.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611623"},"PeriodicalIF":2.3,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10922957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pathology & Oncology Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1